Literature DB >> 18370504

Omega-3 Ethyl Ester Concentrate Decreases Total Apolipoprotein CIII and Increases Antithrombin III in Postmyocardial Infarction Patients.

E Swahn1, H von Schenck, A G Olsson.   

Abstract

This study investigated whether an ethyl ester preparation of fish oil (w-3) could normalise raised plasma concentrations of triglycerides, apolipoprotein CIII on apolipoprotein B-containing particles (LP CIII:B) found in patients with recent acute myocardial infarction. We also studied the effect of fish oil on antithrombin III levels. Out of 75 patients with a plasma triglyceride value >/=2.0 mmol/L, 22 normalised their triglycerides during diet and were therefore not randomised. The remaining patients were randomly assigned to 12 weeks' treatment with a daily dose of 4g w-3 or placebo. Mean plasma triglyceride concentrations were reduced by 24% from 3.10 +/- 1.15 (SD) to 2.53 +/- 0.94 mmol/L (p < 0.001) on w-3 (p < 0.001 vs placebo). The reduction was due to decreases in very low density lipoprotein concentrations. Total apolipoprotein CIII decreased significantly. This was due to reductions in LP CIII:non B concentrations, but the ratio LP CIII:non B/LP CIII:B was unaffected because of a slight insignificant decrease in LP CIII:B. The plasma triglyceride decreasing effect of w-3 could therefore not be due to redistribution of CIII between lipoproteins. Low density lipoprotein (LDL) cholesterol increased significantly with w-3 by 7%, and antithrombin III increased significantly with fish oil. In conclusion, w-3 had a moderate plasma triglyceride lowering effect and increased LDL cholesterol slightly, while antithrombin III increased in patients with hypertriglyceridaemia who had recently experienced a myocardial infarction.

Entities:  

Year:  1998        PMID: 18370504     DOI: 10.2165/00044011-199815060-00003

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  19 in total

1.  The acute effect of a single very high dose of N-3 fatty acids on coagulation and fibrinolysis.

Authors:  J M Møller; N Svaneborg; H H Lervang; K Varming; P Madsen; J Dyerberg; E B Schmidt
Journal:  Thromb Res       Date:  1992-09-01       Impact factor: 3.944

Review 2.  Fish oils in the prevention of atherosclerosis.

Authors:  D H Israel; R Gorlin
Journal:  J Am Coll Cardiol       Date:  1992-01       Impact factor: 24.094

Review 3.  Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review.

Authors:  W S Harris
Journal:  J Lipid Res       Date:  1989-06       Impact factor: 5.922

4.  Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.

Authors:  C S Wang; W J McConathy; H U Kloer; P Alaupovic
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

5.  Quantitative angiographic morphology of coronary stenoses leading to myocardial infarction or unstable angina.

Authors:  R F Wilson; M D Holida; C W White
Journal:  Circulation       Date:  1986-02       Impact factor: 29.690

6.  Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study.

Authors:  G Assmann; H Schulte
Journal:  Am J Cardiol       Date:  1992-09-15       Impact factor: 2.778

7.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.

Authors:  M A DeWood; J Spores; R Notske; L T Mouser; R Burroughs; M S Golden; H T Lang
Journal:  N Engl J Med       Date:  1980-10-16       Impact factor: 91.245

8.  Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E.

Authors:  L Chivot; F Mainard; E Bigot; J M Bard; J L Auget; Y Madec; J C Fruchart
Journal:  Atherosclerosis       Date:  1990-06       Impact factor: 5.162

9.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

Authors:  A Hamsten; B Wiman; U de Faire; M Blombäck
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

10.  HDL2 and HDL3 lipid levels in coronary artery disease.

Authors:  L Wallentin; B Sundin
Journal:  Atherosclerosis       Date:  1986-02       Impact factor: 5.162

View more
  6 in total

Review 1.  Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

Authors:  Werner J Geldenhuys; Li Lin; Altaf S Darvesh; Prabodh Sadana
Journal:  Drug Discov Today       Date:  2016-10-19       Impact factor: 7.851

2.  Fish oil -- how does it reduce plasma triglycerides?

Authors:  Gregory C Shearer; Olga V Savinova; William S Harris
Journal:  Biochim Biophys Acta       Date:  2011-10-25

Review 3.  Current, new and future treatments in dyslipidaemia and atherosclerosis.

Authors:  P H Chong; B S Bachenheimer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

4.  Fish oil supplementation ameliorates fructose-induced hypertriglyceridemia and insulin resistance in adult male rhesus macaques.

Authors:  Andrew A Bremer; Kimber L Stanhope; James L Graham; Bethany P Cummings; Steve B Ampah; Benjamin R Saville; Peter J Havel
Journal:  J Nutr       Date:  2013-10-09       Impact factor: 4.798

5.  Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results.

Authors:  Xiaohong Yang; Sang-Rok Lee; Yun-Seok Choi; Veronica J Alexander; Andres Digenio; Qingqing Yang; Yury I Miller; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2016-02-04       Impact factor: 5.922

Review 6.  Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction.

Authors:  Giulia Chiesa; Marco Busnelli; Stefano Manzini; Cinzia Parolini
Journal:  Mar Drugs       Date:  2016-06-08       Impact factor: 5.118

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.